Meta AnalysisID 2762
石杉碱甲与银杏叶提取物治疗阿尔茨海默病患者的疗效和安全性比较：随机对照试验的网状Meta分析
CRD42015023354
Huperzine A and Ginkgo biloba extract are the commonly used medicines in Alzheimer Disease which come from Chinese herbal medicine. Some studies have already showed efficacy and safety of those two medicines. But we don'
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2762
- Evidence Id
- 11320
- Core Evidence Id
- 11320
- Source Meta Analysis Id
- 2712
- Herb2 Meta Analysis Id
- HBMA002712
- Crd Id
- CRD42015023354
- Title
- Comparative efficacy and safety of Huperzine A and Ginkgo biloba extract in patients with Alzheimer’s disease: a network meta-analysis of randomized controlled trials
- Review Question
- Huperzine A and Ginkgo biloba extract are the commonly used medicines in Alzheimer Disease which come from Chinese herbal medicine. Some studies have already showed efficacy and safety of those two medicines. But we don't know which is better and the relationship between them. This network meta-analysis aim to compare the efficacy and safety of Huperzine A and Ginkgo biloba extract in patients with AD in randomized control studies.
- Study Type Included
- A study will be included if it was a randomized controlled trial.Studies will be excluded if:a) they are animal studies;b) they are reviews,conference presentations or unpublished reports;c)they are duplicated reports;d) there is no control group.
- Condition Being Studied
- Alzheimer disease
- Participant
- Inclusion criteria: The study included patients diagnosed with AD based on the International Classification of Diseases (ICD-10),Diagnostic and Statistical Manual of Mental Disorders(DSM-III, DSM-IIIR and DSM-IV), National Institute of Neurological and Communicative Disorders and Stroke and the AD dementia and Related Disorders Association (NINCD-ADRDA), Chinese Classification of Mental Disorders(CCMD-3) or other well-recognized AD diagnostic criteria at home and abroad were included in the analysis. Exclusion criteria: 1) Combined with other types of dementia or cognitive impairment disease. 2) Age less than 50 years old.
- Animal
- Human Disease Modelled
- Intervention
- Huperzine A or Ginkgo biloba extract
- Comparator Control
- The comparison is placebo or positive treatment drugs.
- Main Outcome
- MMSE (Mini Metal Status Examination), HDS(Hastgawa Dementia Scale), ADAS-cog (Alzheimer’s disease assessment scale-cognitive), WMS (Wechsler Memory Scale) and Activities of Daily Living (ADL).
- Outcome Measure
- Additional Outcome
- Study dropouts and the prevalence of adverse effects.
- Study Method
- Keyword
- Alkaloids; Alzheimer Disease; Biological Products; Ginkgo biloba; Humans; Sesquiterpenes
- Contact
- Dr Feng [email protected]
- Organisational Affiliation
- None None
- Funding Source
- The study is supported by a Grant from the International Science & Technology Cooperation Project of the Ministry of Science and Technology of China (Project Grant no. 2012DFA31760) and the China-Australia International Research Centre for Chinese Medicine, funded by the Guangdong Provincial Academy of Chinese Medical Sciences & Guangdong Provincial Hospital of Chinese Medicine (GPACMS & GPHCM), Guangdong, China, and RMIT University, Australia.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Australia, China
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2015-06-10
- Anticipated Start Date
- 2015-07-01
- Anticipated Completion Date
- 2015-11-30
- Title Cn
- 石杉碱甲与银杏叶提取物治疗阿尔茨海默病患者的疗效和安全性比较：随机对照试验的网状Meta分析
- Title En
- Comparative efficacy and safety of Huperzine A and Ginkgo biloba extract in patients with Alzheimer’s disease: a network meta-analysis of randomized controlled trials
- Bilingual Status
- complete